Skip to main content

Bret H. Goodpaster

Bret H. Goodpaster

Scientific Director

Bret H. Goodpaster


Bret Goodpaster, Ph.D. investigates the pathophysiology of human aging, obesity, insulin resistance, and diabetes, and the biological mechanisms underlying the health benefits of exercise. 

Dr. Goodpaster has received a number of awards and honors for his work, including the Nathan Shock Award from the National Institute of Aging in 2008. He is particularly well known for “the athlete’s paradox” which has shifted the paradigm in type 2 diabetes research to investigate, how and why does fat accumulation in muscle cause insulin resistance in some subjects but not others?  Which are the good fats and which are the bad fats? 

Dr. Goodpaster has published >250 peer-reviewed papers, review articles and book chapters, has served on several Editorial Boards, and is currently an Associate Editor for Diabetologia. He has served on grant review panels for the NIH and the American Diabetes Association. 

Dr. Goodpaster obtained a B.S. in Biology from Purdue, and after completing a Pre-doctoral Fellowship at Maastricht University in the Netherlands, received his Ph.D. in Human Bioenergetics from Ball State University. Prior to coming to the AdventHealth TRI-MD, he was Professor of Medicine and UPMC Chair for Diabetes and Metabolism Research at the University of Pittsburgh.

Associated Clinical Trials


Icon for trial | RISE

This is a randomized, double-blind, placebo-controlled, single-center, repeat-dose, parallel-group study in overweight or obese subjects with prediabetes. The study is designed to assess the effect of the combination of REGN247 ...


Icon for trial | BL20

The purpose of this research study is to examine how a complete oral nutritional supplement, with or without AN777(an innovative nutritional ingredient), can slow the loss of muscle mass that occurs during 10 days of bed rest i ...


Icon for trial | MIRAGE

The purpose of this study is to collect data to help researchers understand how diet and exercise may affect certain body processes (fat metabolism and insulin resistance) which lead to the development of type 2 diabetes. ...


Icon for trial | BIDI

To evaluate the effectiveness and safety of an investigational drug, Bimagrumab (study drug) compared to placebo to decrease total body fat mass, increase muscle mass and improve glycemic control in overweight and obese individ ...


Icon for trial | INVESTIGAIT

The purpose of this study is to find out if the drug bimagrumab (BYM338) is safe and has beneficial (positive) effects in people with a lower than normal amount of muscle for their age and difficulty walking or climbing stairs. ...


Icon for trial | INVESTIGAIT EXT

The purpose of the study is to evaluate how long the effect on muscle size and strength lasts, when bimagrumab treatment is stopped after 24 weeks.


Icon for trial | PRONUTRIA

To assess the effects of two different amounts of a proprietary nutritive protein supplement on muscle growth in elderly people.


Icon for trial | MoTrPAC

This study is currently enrolling.

This national study measures the changes in the molecules in the body that occur with exercise. To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following cri ...